BullFrog AI issues shareholder letter highlighting recent progress, outlook

BullFrog AI (BFRG) issued a letter to shareholders from founder and CEO Vin Singh stating the company has secured the financial runway to execute its strategy into late 2027 and is in active discussions with pharmaceutical and biotechnology organizations. “BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations,” said Vin Singh, founder and CEO. “We just closed our first agreement with a top 5 global pharmaceutical company, secured the financial runway to execute our strategy into late 2027, and are deeply engaged with an industry that is no longer evaluating whether to embrace AI-driven drug discovery – but deciding with whom”.